These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35189668)

  • 1. Expanded eligibility for emerging therapies in sickle cell disease in the UK - crizanlizumab and voxelotor.
    Vora SM; Boyd S; Denny N; Jackson E; Roy NBA; Howard J; Lugthart S
    Br J Haematol; 2022 May; 197(4):502-504. PubMed ID: 35189668
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L-glutamine, voxelotor, and crizanlizumab in sickle cell disease.
    Chen M; Hankins JS; Zhang M; Ataga KI
    Am J Hematol; 2024 Feb; 99(2):E37-E41. PubMed ID: 37950855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two drugs for sickle cell disease.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):51-52. PubMed ID: 32324178
    [No Abstract]   [Full Text] [Related]  

  • 4. Voxelotor for the Treatment of Sickle Cell Disease.
    Fantasia HC; Morse BL
    Nurs Womens Health; 2020 Jun; 24(3):233-237. PubMed ID: 32387142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.
    Howard J; Ataga KI; Brown RC; Achebe M; Nduba V; El-Beshlawy A; Hassab H; Agodoa I; Tonda M; Gray S; Lehrer-Graiwer J; Vichinsky E
    Lancet Haematol; 2021 May; 8(5):e323-e333. PubMed ID: 33838113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spotlight Commentary - Voxelotor: A new kid on the block in the treatment of sickle cell disease.
    Çanak B; Eşkazan AE
    Br J Clin Pharmacol; 2022 Jun; 88(6):2564-2565. PubMed ID: 35158414
    [No Abstract]   [Full Text] [Related]  

  • 7. An update review of new therapies in sickle cell disease: the prospects for drug combinations.
    Lugthart S; Ginete C; Kuona P; Brito M; Inusa BPD
    Expert Opin Pharmacother; 2024 Feb; 25(2):157-170. PubMed ID: 38344818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. l-glutamine, crizanlizumab, voxelotor, and cell-based therapy for adult sickle cell disease: Hype or hope?
    Leibovitch JN; Tambe AV; Cimpeanu E; Poplawska M; Jafri F; Dutta D; Lim SH
    Blood Rev; 2022 May; 53():100925. PubMed ID: 34991920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voxelotor treatment of a patient with sickle cell disease and very severe anemia.
    Shet AS; Mendelsohn L; Harper J; Ostrowski D; Henry ER; Gwaabe E; Nichols J; Alayash AI; Eaton WA; Thein SL
    Am J Hematol; 2019 Apr; 94(4):E88-E90. PubMed ID: 30592074
    [No Abstract]   [Full Text] [Related]  

  • 10. Two New Drugs for Sickle Cell Disease.
    Aschenbrenner DS
    Am J Nurs; 2020 Mar; 120(3):24. PubMed ID: 32079792
    [No Abstract]   [Full Text] [Related]  

  • 11. Voxelotor use in adults with sickle cell disease in a real-world setting.
    Curtis SA; Betancourt J; Kottapalli N; Campbell S; Minniti C
    Am J Hematol; 2022 Mar; 97(3):E125-E128. PubMed ID: 34967959
    [No Abstract]   [Full Text] [Related]  

  • 12. Sickle cell: NICE approves voxelotor after initially rejecting it over uncertain evidence.
    Mahase E
    BMJ; 2024 May; 385():q1015. PubMed ID: 38702062
    [No Abstract]   [Full Text] [Related]  

  • 13. A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
    Vichinsky E; Hoppe CC; Ataga KI; Ware RE; Nduba V; El-Beshlawy A; Hassab H; Achebe MM; Alkindi S; Brown RC; Diuguid DL; Telfer P; Tsitsikas DA; Elghandour A; Gordeuk VR; Kanter J; Abboud MR; Lehrer-Graiwer J; Tonda M; Intondi A; Tong B; Howard J;
    N Engl J Med; 2019 Aug; 381(6):509-519. PubMed ID: 31199090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Practice Patterns in Sickle Cell Disease Treatment: Disease-modifying and Potentially Curative Therapies.
    Sánchez LM; Morrone K; Frei-Jones M; Fasipe TA
    J Pediatr Hematol Oncol; 2024 Jul; 46(5):e277-e283. PubMed ID: 38718300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
    Han J; Saraf SL; Gordeuk VR
    Pharmacotherapy; 2020 Jun; 40(6):525-534. PubMed ID: 32343424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease.
    Howard J; Hemmaway CJ; Telfer P; Layton DM; Porter J; Awogbade M; Mant T; Gretler DD; Dufu K; Hutchaleelaha A; Patel M; Siu V; Dixon S; Landsman N; Tonda M; Lehrer-Graiwer J
    Blood; 2019 Apr; 133(17):1865-1875. PubMed ID: 30655275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voxelotor and albuminuria in adults with sickle cell anaemia.
    Han J; Molokie RE; Hussain F; Njoku F; Gordeuk VR; Saraf SL
    Br J Haematol; 2022 Jun; 197(5):e63-e64. PubMed ID: 35156191
    [No Abstract]   [Full Text] [Related]  

  • 18. Voxelotor: A Novel Treatment for Sickle Cell Disease.
    Herity LB; Vaughan DM; Rodriguez LR; Lowe DK
    Ann Pharmacother; 2021 Feb; 55(2):240-245. PubMed ID: 32674605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.
    Rutherford-Parker NJ; Campbell ST; Colby JM; Shajani-Yi Z
    Am J Clin Pathol; 2020 Oct; 154(5):627-634. PubMed ID: 32561909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Voxelotor for the treatment of sickle cell disease.
    Vissa M; Vichinsky E
    Expert Rev Hematol; 2021 Mar; 14(3):253-262. PubMed ID: 33602029
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.